Collegium Pharmaceutical (NASDAQ:COLL) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Thursday, Zacks.com reports. The firm presently has a $13.00 price objective on the specialty pharmaceutical company’s stock. Zacks Investment Research‘s price target points to a potential upside of 10.26% from the company’s current price.
According to Zacks, “Collegium Pharmaceutical Inc. is a specialty pharmaceutical company. It develops and commercializes prescription and over-the-counter pharmaceuticals for the treatment of central nervous system, respiratory and skin related disorders. The Company’s product candidate consists of COL-195, COL-196, COL-171, COL-003 and COL-172 which are in different clinical trial. It developed a formulation platform technology, DETERx, for the treatment of chronic pain. Collegium Pharmaceutical Inc. is based in CUMBERLAND, United States. “
Several other equities research analysts have also recently commented on the company. BidaskClub raised Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Tuesday, August 13th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $24.00 price objective (down from $35.00) on shares of Collegium Pharmaceutical in a research report on Thursday, August 8th. Needham & Company LLC set a $33.00 price objective on Collegium Pharmaceutical and gave the company a “buy” rating in a research report on Friday, September 27th. William Blair reaffirmed a “buy” rating on shares of Collegium Pharmaceutical in a research report on Tuesday, September 17th. Finally, ValuEngine raised Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Three equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $24.00.
Collegium Pharmaceutical stock opened at $11.79 on Thursday. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.25 and a quick ratio of 1.20. Collegium Pharmaceutical has a one year low of $10.01 and a one year high of $19.83. The stock has a market capitalization of $384.58 million, a PE ratio of -9.91 and a beta of 0.52. The business’s fifty day moving average is $11.47 and its 200 day moving average is $12.46.
Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings data on Wednesday, August 7th. The specialty pharmaceutical company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.05. Collegium Pharmaceutical had a negative return on equity of 26.10% and a negative net margin of 7.45%. The company had revenue of $75.04 million for the quarter, compared to analysts’ expectations of $75.77 million. During the same period last year, the firm posted ($0.40) earnings per share. Collegium Pharmaceutical’s revenue was up 2.7% compared to the same quarter last year. As a group, sell-side analysts expect that Collegium Pharmaceutical will post -0.37 EPS for the current fiscal year.
In other Collegium Pharmaceutical news, Director Michael Thomas Heffernan sold 25,000 shares of the firm’s stock in a transaction dated Monday, July 15th. The stock was sold at an average price of $11.26, for a total value of $281,500.00. Following the transaction, the director now directly owns 132,069 shares of the company’s stock, valued at $1,487,096.94. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director David Hirsch sold 22,106 shares of the firm’s stock in a transaction dated Thursday, August 29th. The stock was sold at an average price of $11.65, for a total value of $257,534.90. Following the completion of the transaction, the director now directly owns 64,223 shares in the company, valued at $748,197.95. The disclosure for this sale can be found here. Company insiders own 8.08% of the company’s stock.
A number of large investors have recently made changes to their positions in the business. First Quadrant L P CA boosted its position in Collegium Pharmaceutical by 87.2% in the second quarter. First Quadrant L P CA now owns 4,484 shares of the specialty pharmaceutical company’s stock worth $59,000 after purchasing an additional 2,089 shares during the last quarter. DekaBank Deutsche Girozentrale boosted its position in Collegium Pharmaceutical by 22.2% in the first quarter. DekaBank Deutsche Girozentrale now owns 13,200 shares of the specialty pharmaceutical company’s stock worth $221,000 after purchasing an additional 2,400 shares during the last quarter. Northern Trust Corp boosted its position in Collegium Pharmaceutical by 1.1% in the second quarter. Northern Trust Corp now owns 387,440 shares of the specialty pharmaceutical company’s stock worth $5,095,000 after purchasing an additional 4,201 shares during the last quarter. Royal Bank of Canada boosted its position in Collegium Pharmaceutical by 33.7% in the second quarter. Royal Bank of Canada now owns 17,275 shares of the specialty pharmaceutical company’s stock worth $227,000 after purchasing an additional 4,350 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its position in Collegium Pharmaceutical by 2.4% in the second quarter. Bank of New York Mellon Corp now owns 189,543 shares of the specialty pharmaceutical company’s stock worth $2,492,000 after purchasing an additional 4,524 shares during the last quarter. 92.08% of the stock is currently owned by institutional investors and hedge funds.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, heating, and injecting.
Read More: Margin
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.